Briefing
NCCN 2026 prostate guideline adds a table of FDA-cleared PET tracers
The NCCN 2026 prostate cancer update presented at the NCCN Annual Conference adds a table of FDA-cleared PET imaging tracer studies, in a discussion that noted prior registration trials used conventional imaging rather than PSMA PET.